In a deal worth upto US$265 M, Theravance Biopharma has secured Mylan as a partner for the development and commercialisation of TD-4208, its Phase III-ready long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease that was previously licensed to GlaxoSmithKline. If approved,TD-4208 will become the first commercially available once-daily nebulised LAMA therapy for the disease.The drug candidate is well suited to Mylan given its expertise in manufacturing and marketing complex respiratory products such as Perforomist® (formoterol fumarate) inhalation solution.